Adverse events were frequent (80 to 97% versus 63 to 100% for GLP-1 RA versus placebo); most were gastrointestinal-related, including nausea, vomiting, diarrhea, and constipation. "Our results ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Coya Therapeutics expands its pipeline, advancing COYA 303 with a dual immunomodulatory mechanism for inflammatory ... glucagon-like-peptide-1 receptor agonist (GLP-1 RA) designed for subcutaneous ...